What 60 Minutes Got Wrong About Harvard and the Biomedical Research Enterprise

A recent segment was a sad attempt to cloak the shortcomings of academic science in hype, sentimentality, and public relations theater.

N early everyone has had a loved one afflicted by cancer. Mention the word cancer, and people instinctively feel sympathy, fear, or hope.

When I was a student, I remember thinking about sick cancer patients and being brought almost to tears. That emotion was part of what drew me into cancer research; it felt like the most meaningful way to use science to help people.

But over time, I learned how that emotion gets monetized. Money pours into anything even vaguely associated with cancer research. Federal grants with the word cancer in the body are treated as sacred. Vast sums flow into university cancer centers with layers of bureaucracy, fundraising arms, and administrators who never see a patient or do a single piece of research. There are countless cancer charities and nonprofit academic cancer centers where executives make exorbitant pay. Questioning whether any of this actually helps patients or advances science is treated as heresy.

The academic research enterprise feeds on empathy. As much as it pains me to write, the good intentions that once drew idealists to the field have been industrialized into a business model.

That model was on full display in a recent 60 Minutes segment that turned Harvard’s scientists into stage props — a public relations production designed to shill for money and convince the public that the richest academic institution on earth is somehow underfunded.

Joan Brugge, a respected cell biologist, was featured on the show as making breakthroughs in cancer on behalf of Harvard University — a narrative the show embraced without skepticism. In truth, her legacy lies in fundamental cell biology. She has done solid work but little that has directly changed cancer therapy or patient outcomes. Presenting her research as crucial to curing breast cancer was misleading and emblematic of the deeper pathology in academic science: the compulsion to oversell. I worked with her and her laboratory around 15 years ago when I was a research fellow and later an instructor on the faculty at Harvard. I actually published, as the lead and corresponding author, what became her most cited original research paper. She is a capable scientist, but the way her work was portrayed in the segment bore little resemblance to reality.

Universities and their faculty have learned that success in today’s system depends not as much on actually doing science but on marketing the perception of science — framing even routine findings as lifesaving advances. “Cancer” has become a brand, a universal justification for more funding and prestige. The public sees heroism; insiders see dollar signs. One of the strangest features of this ecosystem is how many researchers who do pure basic science — work with no foreseeable medical application — nevertheless frame their research as “curing cancer.”

This is a problem not because basic science lacks value — foundational, curiosity-driven research is one of the most important things a society can fund. The problem is that the purpose of the work is rarely stated honestly. Taxpayers and donors are told they are supporting cancer cures when, in reality, they’re supporting studies on cell signaling, structural biology, or organismal physiology. Those projects may have scientific merit, but the justification offered to the public is tenuous. That obfuscation hides a deeper, more fundamental question: How much public funding and philanthropy should go toward basic science itself?

That is a legitimate debate worth having. But when so much research is sold as “curing cancer,” the question never even arises. The framing erases the distinction between exploratory research and direct medical progress. This blurring is one reason why, despite the money spent, we do not have enough progress in understanding fundamental biology or a reduction in cancer mortality.

The incentives reward exaggeration. Everyone plays along because transparency would threaten the financial architecture of the entire enterprise. The public thinks it is funding medical breakthroughs; universities know the money is sustaining an enormous ecosystem of labs, trainees, administrators, and overhead. Basic scientists describe themselves as working on cancer because that is the only language the system pays for.

At 76, Brugge represents a generation that continues to command major funding on the basis of past discoveries while younger scientists struggle to stay afloat in temporary, grant-dependent positions. NIH funding rewards inertia and seniority, not boldness or efficiency, and universities have no incentive to change because the money from those grants sustains vast administrative payrolls.

David Liu, another scientist featured in the piece, came across better — a genuinely talented researcher whose work on gene-editing reflects real creativity and medical impact. His demeanor reinforced the image of the quirky, idealistic scientist. That’s not an affectation. I remember visiting his house once during an admitted-students’ recruitment event for Harvard’s doctoral program in chemistry. He was showing a group of us the video games he enjoyed and the latest technological gadgets he had set up — a small but memorable confirmation that he exhibited the archetype of the technically obsessed, intellectually curious scientist. In that sense, the profile didn’t distort him.

But the framing was still misleading. Scientists like Liu are rare, and their success doesn’t validate Harvard and the biomedical research enterprise; it exposes how dependent its public image has become on a handful of outliers. Academia holds them up as proof that the enterprise works when, in reality, they are statistical anomalies floating atop an ocean of inefficiency.

Liu could move his lab tomorrow to an independent institute or a private venture and continue doing the same science — likely with fewer obstacles and less bureaucracy. His anecdotal success doesn’t validate academia’s efficiency; it arguably shows that innovation can happen despite the system, not because of it.

It’s also important to recognize that Liu has benefited heavily from Harvard’s brand. The name alone recruits top students and attracts funding. But that prestige is inherited from an earlier era — not created by today’s bureaucratic university. As the brand erodes, as it has in recent years, scientists like Liu will be less inclined to stay. Harvard leans on people like him to project vitality, but his presence is borrowed credibility, not evidence of a healthy system.

This raises a deeper question that 60 Minutes never asked: How much of the money awarded to biomedical research actually results in work of Liu’s caliber? We spend tens of billions of public dollars each year, yet only a small fraction produces foundational discoveries or widely beneficial technologies. The vast majority may be consumed by administrative expansion, soft-money positions, bloated cancer centers, and incremental or redundant projects framed as breakthroughs to keep the funding cycle alive. The output-to-dollar ratio is far lower than the public is led to believe — and the few genuine innovators are used as marketing tools to justify the inefficiencies surrounding them.

The segment’s most disingenuous moments came from Donald Ingber and Steven Pinker. Ingber’s suggestion that academia has moved past the woke era is either naïve or self-serving; the same ideological and bureaucratic forces remain intact, merely rebranded under new slogans. Pinker, meanwhile, has positioned himself as the anti-woke reformer capable of changing the system from within. It’s a comforting story for donors and alumni, but it ignores reality.

Modern universities are not communities of scholars; they are corporations with opaque bureaucracies, large legal and lobbying departments, and marketing offices. They answer to endowments, hospital revenue, and federal contracts, not to the pursuit of truth. The idea that reform can come from within, from the same people who built and benefit from the control of this structure, is wishful thinking.

What 60 Minutes offered wasn’t journalism; it was advertising. It sold the illusion that academic science is still powered by curiosity and altruism. It replaced analysis with myth — Harvard’s labs as sanctuaries of intellect, its scientists as moral heroes. The real picture is bleaker: sprawling research conglomerates, administrative empires, and laboratories trapped in a perpetual cycle of grant-writing and image management.

Cancer research, more than any other field, reveals how empathy is converted into capital. Billions in federal funds are sent to “centers,” “initiatives,” and “moon shots” that largely enrich universities and their administrative class. Each year brings another headline about ”major progress,” yet survival rates for most metastatic cancers remain unchanged or very modestly improved. The outputs that matter — reproducible and generalizable discoveries, affordable therapies, measurable patient benefit — grow slower than the budgets and bureaucracies built to chase them.

The tragedy is that the public still believes. People think that their donations, their taxes, and their faith in science are fueling a collective fight against disease. In reality, they are underwriting a system that spends more on administration, branding, and compliance than on the experiments themselves.

Reform won’t come from Harvard’s media machine or from panels of senior academics congratulating themselves for incremental change. It will come from building leaner, more accountable institutions that prioritize truth over image management; from funding people, not bureaucracies, and restoring honesty about what science can and cannot do.

That means separating genuine discovery from marketing. It also means facing an uncomfortable truth: the biomedical establishment has become addicted to public sympathy.

The 60 Minutes piece wasn’t a celebration of science — it was damage control. A carefully crafted story to reassure viewers that the old institutions still deserve their trust and money. But the real story of American biomedical research is one of drift: a system that feeds on empathy while starving innovation, that confuses visibility with virtue, and that calls marketing itself impact.

Cancer research deserves better. Science deserves better. And the public deserves to know where its hope and its dollars are actually going.